Reflecting on NHS experience to date with CAR T – Thinkpiece 2.0
The report "Learning the lessons of today to deliver the treatments of tomorrow" is the result of the excellent collaboration with the NHS and our industry partners. Funded by the Cell and Gene Therapy Catapult, Gilead Sciences and Novartis, it reflects the experience to date from the supply of licensed CAR-T products to the NHS.
The report explores the perspectives of the NHS and industry partners on the adoption of CAR-T in the UK and is based on information gathered from interviews conducted across the NHS as well as insights gained from Kite, a Gilead Sciences company and Novartis, plus a number of other CAR-T manufacturers. It outlines the successes and challenges of the NHS and provides unique insights on CAR-T therapy delivery, as well as recommendations to ensure the NHS is ready for the growing wave of CAR-T therapies and ATMPs more generally.
Click here or the image below to review the report on the ATTC website.
